A Phase I Open-label Clinical Trial, Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 08 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HVEGF26 104 RFASE (Primary)
Indications Adenoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Hypopharyngeal cancer; Liver cancer; Neuroendocrine tumours; Oesophageal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors Immunovo

11 Nov 2020 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
11 Nov 2020 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2020.
17 Mar 2017 Planned End Date changed from 1 Apr 2016 to 1 Dec 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com